ÌÇÐÄvlog

Object moved to here.

Surgical Management of Gastric Cancer: A Review | Oncology | JAMA Surgery | ÌÇÐÄvlog

ÌÇÐÄvlog

[Skip to Navigation]
Sign In
1.
Coggon ÌýD, Barker ÌýDJ, Cole ÌýRB, Nelson ÌýM. ÌýStomach cancer and food storage.Ìý ÌýJ Natl Cancer Inst. 1989;81(15):1178-1182. doi:
2.
Parsonnet ÌýJ, Vandersteen ÌýD, Goates ÌýJ, Sibley ÌýRK, Pritikin ÌýJ, Chang ÌýY. ÌýHelicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas.Ìý ÌýJ Natl Cancer Inst. 1991;83(9):640-643. doi:
3.
Wanebo ÌýHJ, Kennedy ÌýBJ, Chmiel ÌýJ, Steele ÌýG ÌýJr, Winchester ÌýD, Osteen ÌýR. ÌýCancer of the stomach. a patient care study by the American College of Surgeons.Ìý ÌýAnn Surg. 1993;218(5):583-592. doi:
4.
Bray ÌýF, Ferlay ÌýJ, Soerjomataram ÌýI, Siegel ÌýRL, Torre ÌýLA, Jemal ÌýA. ÌýGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.Ìý ÌýCA Cancer J Clin. 2018;68(6):394-424. doi:
5.
Siegel ÌýRL, Miller ÌýKD, Jemal ÌýA. ÌýCancer statistics, 2019.Ìý ÌýCA Cancer J Clin. 2019;69(1):7-34. doi:
6.
Van Cutsem ÌýE, Sagaert ÌýX, Topal ÌýB, Haustermans ÌýK, Prenen ÌýH. ÌýGastric cancer.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 2016;388(10060):2654-2664. doi:
7.
Abdelfatah ÌýMM, Barakat ÌýM, Lee ÌýH, Ìýet al. ÌýThe incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis.Ìý ÌýGastrointest Endosc. 2018;87(2):338-347. doi:
8.
Kamarajah ÌýSK, Markar ÌýSR, Phillips ÌýAW, Salti ÌýGI, Dahdaleh ÌýFS. ÌýLocal endoscopic resection is inferior to gastrectomy for early clinical stage T1a and T1b gastric adenocarcinoma: a propensity-matched study.Ìý ÌýAnn Surg Oncol. 2021;28(6):2992-2998. doi:
9.
Manner ÌýH, Rabenstein ÌýT, May ÌýA, Ìýet al. ÌýLong-term results of endoscopic resection in early gastric cancer: the Western experience.Ìý ÌýAm J Gastroenterol. 2009;104(3):566-573.
10.
Uedo ÌýN, Iishi ÌýH, Tatsuta ÌýM, Ìýet al. ÌýLong-term outcomes after endoscopic mucosal resection for early gastric cancer.Ìý ÌýGastric Cancer. 2006;9(2):88-92. doi:
11.
Japanese Gastric Cancer Association. ÌýJapanese Gastric Cancer Treatment Guidelines 2014 (ver. 4).Ìý ÌýGastric Cancer. 2017;20(1):1-19. doi:
12.
Smyth ÌýEC, Verheij ÌýM, Allum ÌýW, Cunningham ÌýD, Cervantes ÌýA, Arnold ÌýD; ESMO Guidelines Committee. ÌýGastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.Ìý ÌýAnn Oncol. 2016;27(suppl 5):v38-v49. doi:
13.
Ajani ÌýJA, D’Amico ÌýTA, Bentrem ÌýDJ, Ìýet al. ÌýEsophageal and esophagogastric junction cancers, version 2.2021, NCCN clinical practice guidelines oncology.Ìý ÌýJ Natl Compr Canc Netw. 2019;17(7):855-883.doi:
14.
Fukase ÌýK, Kato ÌýM, Kikuchi ÌýS, Ìýet al; Japan Gast Study Group. ÌýEffect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 2008;372(9636):392-397. doi:
15.
Bausys ÌýR, Bausys ÌýA, Vysniauskaite ÌýI, Ìýet al. ÌýRisk factors for lymph node metastasis in early gastric cancer patients: report from Eastern Europe country—Lithuania.Ìý ÌýBMC Surg. 2017;17(1):108. doi:
16.
Jung ÌýDH, Huh ÌýCW, Kim ÌýJ-H, Ìýet al. ÌýRisk-stratification model based on lymph node metastasis after noncurative endoscopic resection for early gastric cancer.Ìý ÌýAnn Surg Oncol. 2017;24(6):1643-1649. doi:
17.
Takeuchi ÌýH, Kitagawa ÌýY. ÌýSentinel lymph node biopsy in gastric cancer.Ìý ÌýCancer J. 2015;21(1):21-24. doi:
18.
Miyashiro ÌýI, Hiratsuka ÌýM, Sasako ÌýM, Ìýet al; Gastric Cancer Surgical Study Group (GCSSG) in the Japan Clinical Oncology Group (JCOG). ÌýHigh false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302.Ìý ÌýGastric Cancer. 2014;17(2):316-323. doi:
19.
Kitagawa ÌýY, Takeuchi ÌýH, Takagi ÌýY, Ìýet al. ÌýSentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.Ìý ÌýJ Clin Oncol. 2013;31(29):3704-3710. doi:
20.
Ryu ÌýKW, Eom ÌýBW, Nam ÌýB-H, Ìýet al. ÌýIs the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? a meta-analysis of feasibility studies.Ìý ÌýJ Surg Oncol. 2011;104(6):578-584. doi:
21.
Park ÌýJY, Kim ÌýY-W, Ryu ÌýKW, Ìýet al. ÌýAssessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer—a multicenter randomized phase III clinical trial (SENORITA trial) protocol.Ìý ÌýBMC Cancer. 2016;16:340. doi:
22.
Slagter ÌýAE, Jansen ÌýEPM, van Laarhoven ÌýHWM, Ìýet al. ÌýCRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs neoadjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.Ìý ÌýBMC Cancer. 2018;18(1):877. doi:
23.
Leong ÌýT, Smithers ÌýBM, Haustermans ÌýK, Ìýet al. ÌýTOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC, and CCTG.Ìý ÌýAnn Surg Oncol. 2017;24(8):2252-2258. doi:
24.
Cui ÌýS-Z, Liang ÌýH, Li ÌýY, Ìýet al; Chinese Peritoneal Oncology Study Group. ÌýPILGRIM: Phase III Clinical Trial in Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer Patients After Radical Gastrectomy With D2 Lymphadenectomy (HIPEC-01).Ìý ÌýJ Clin Oncol. 2020;38(15):4538. doi:
25.
Al-Batran ÌýSE, Goetze ÌýTO, Mueller ÌýDW, Ìýet al. ÌýThe RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction—a phase III trial of the German AIO/CAO-V/CAOGI.Ìý ÌýBMC Cancer. 2017;17(1):893. doi:
26.
Furukawa ÌýH, Hiratsuka ÌýM, Imaoka ÌýS, Ìýet al. ÌýPhase II study of limited surgery for early gastric cancer: segmental gastric resection.Ìý ÌýAnn Surg Oncol. 1999;6(2):166-170. doi:
27.
Isozaki ÌýH, Matsumoto ÌýS, Murakami ÌýS, Ìýet al. ÌýDiminished gastric resection preserves better quality of life in patients with early gastric cancer.Ìý ÌýActa Med Okayama. 2016;70(2):119-130.
28.
Abe ÌýN, Takeuchi ÌýH, Ohki ÌýA, Ìýet al. ÌýLong-term outcomes of combination of endoscopic submucosal dissection and laparoscopic lymph node dissection without gastrectomy for early gastric cancer patients who have a potential risk of lymph node metastasis.Ìý ÌýGastrointest Endosc. 2011;74(4):792-797. doi:
29.
Zhao ÌýL, Ling ÌýR, Chen ÌýJ, Ìýet al. ÌýClinical outcomes of proximal gastrectomy versus total gastrectomy for proximal gastric cancer: a systematic review and meta-analysis.Ìý ÌýDig Surg. 2021;38(1):1-13. doi:
30.
Japanese Gastric Cancer Association. ÌýJapanese classification of gastric carcinoma: 3rd English edition.Ìý ÌýGastric Cancer. 2011;14(2):101-112. doi:
31.
Cuschieri ÌýA, Fayers ÌýP, Fielding ÌýJ, Ìýet al. ÌýPostoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. the Surgical Cooperative Group.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 1996;347(9007):995-999. doi:
32.
Cuschieri ÌýA, Weeden ÌýS, Fielding ÌýJ, Ìýet al; Surgical Co-operative Group. ÌýPatient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial.Ìý ÌýBr J Cancer. 1999;79(9-10):1522-1530. doi:
33.
Bonenkamp ÌýJJ, Hermans ÌýJ, Sasako ÌýM, Ìýet al; Dutch Gastric Cancer Group. ÌýExtended lymph-node dissection for gastric cancer.Ìý ÌýN Engl J Med. 1999;340(12):908-914. doi:
34.
Songun ÌýI, Putter ÌýH, Kranenbarg ÌýEM, Sasako ÌýM, van de Velde ÌýCJ. ÌýSurgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Oncol. 2010;11(5):439-449. doi:
35.
Dikken ÌýJL, Jansen ÌýEP, Cats ÌýA, Ìýet al. ÌýImpact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.Ìý ÌýJ Clin Oncol. 2010;28(14):2430-2436. doi:
36.
Woo ÌýY, Goldner ÌýB, Son ÌýT, Ìýet al. ÌýWestern validation of a novel gastric cancer prognosis prediction model in US gastric cancer patients.Ìý ÌýJ Am Coll Surg. 2018;226(3):252-258. doi:
37.
Wang ÌýJ. ÌýThe winner for D2 lymph node dissection in distal gastrectomy—anatomic landmarks vs number of examined lymph nodes.Ìý ÌýArt Surg. Published online December 19, 2017. doi:
38.
Sano ÌýT, Sasako ÌýM, Yamamoto ÌýS, Ìýet al. ÌýGastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501.Ìý ÌýJ Clin Oncol. 2004;22(14):2767-2773. doi:
39.
Hyung ÌýWJ, Yang ÌýH-K, Park ÌýY-K, Ìýet al; Korean Laparoendoscopic Gastrointestinal Surgery Study Group. ÌýLong-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial.Ìý ÌýJ Clin Oncol. 2020;38(28):3304-3313. doi:
40.
Kim ÌýW, Kim ÌýH-H, Han ÌýS-U, Ìýet al; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. ÌýDecreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01).Ìý ÌýAnn Surg. 2016;263(1):28-35. doi:
41.
Yu ÌýJ, Huang ÌýC, Sun ÌýY, Ìýet al; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. ÌýEffect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial.Ìý Ìý´³´¡²Ñ´¡. 2019;321(20):1983-1992. doi:
42.
Kelly ÌýKJ, Selby ÌýL, Chou ÌýJF, Ìýet al. ÌýLaparoscopic versus open gastrectomy for gastric adenocarcinoma in the West: a case-control study.Ìý ÌýAnn Surg Oncol. 2015;22(11):3590-3596. doi:
43.
van der Veen ÌýA, Brenkman ÌýHJF, Seesing ÌýMFJ, Ìýet al; LOGICA Study Group. ÌýLaparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): a multicenter randomized clinical trial.Ìý ÌýJ Clin Oncol. 2021;39(9):978-989. doi:
44.
Kim ÌýH-G, Park ÌýJ-H, Jeong ÌýS-H, Ìýet al. ÌýTotally laparoscopic distal gastrectomy after learning curve completion: comparison with laparoscopy-assisted distal gastrectomy.Ìý ÌýJ Gastric Cancer. 2013;13(1):26-33. doi:
45.
Jung ÌýDH, Son ÌýS-Y, Park ÌýYS, Ìýet al. ÌýThe learning curve associated with laparoscopic total gastrectomy.Ìý ÌýGastric Cancer. 2016;19(1):264-272. doi:
46.
Kim ÌýH-I, Han ÌýS-U, Yang ÌýH-K, Ìýet al. ÌýMulticenter prospective comparative study of robotic versus laparoscopic gastrectomy for gastric adenocarcinoma.Ìý ÌýAnn Surg. 2016;263(1):103-109. doi:
47.
Li ÌýZ-Y, Zhou ÌýY-B, Li ÌýT-Y, Ìýet al; Robotic, Laparoscopic Surgery Committee of Chinese Research Hospital Association. ÌýRobotic gastrectomy vs laparoscopic gastrectomy for gastric cancer: a multicenter cohort study of 5402 patients in China.Ìý ÌýAnn Surg. 2021. doi:
48.
Kim ÌýMS, Kim ÌýWJ, Hyung ÌýWJ, Ìýet al. ÌýComprehensive learning curve of robotic surgery: discovery from a multicenter prospective trial of robotic gastrectomy.Ìý ÌýAnn Surg. 2021;273(5):949-956. doi:
49.
Strong ÌýVE, Russo ÌýAE, Nakauchi ÌýM, Ìýet al. ÌýRobotic gastrectomy for gastric adenocarcinoma in the USA: insights and oncologic outcomes in 220 patients.Ìý ÌýAnn Surg Oncol. 2021;28(2):742-750. doi:
50.
Cunningham ÌýD, Allum ÌýWH, Stenning ÌýSP, Ìýet al; MAGIC Trial Participants. ÌýPerioperative chemotherapy vs surgery alone for resectable gastroesophageal cancer.Ìý ÌýN Engl J Med. 2006;355(1):11-20. doi:
51.
Al-Batran ÌýSE, Homann ÌýN, Pauligk ÌýC, Ìýet al; FLOT4-AIO Investigators. ÌýPerioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 2019;393(10184):1948-1957. doi:
52.
Cats ÌýA, Jansen ÌýEPM, van Grieken ÌýNCT, Ìýet al; CRITICS investigators. ÌýChemotherapy vs chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Oncol. 2018;19(5):616-628. doi:
53.
Rivera ÌýF, Izquierdo-Manuel ÌýM, García-Alfonso ÌýP, Ìýet al. ÌýPerioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.Ìý ÌýEur J Cancer. 2021;145:158-167. doi:
54.
Shitara ÌýK, Van Cutsem ÌýE, Bang ÌýYJ, Ìýet al. ÌýEfficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.Ìý Ìý´³´¡²Ñ´¡ Oncol. 2020;6(10):1571-1580. doi:
55.
Ajani ÌýJA, Winter ÌýK, Okawara ÌýGS, Ìýet al. ÌýPhase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.Ìý ÌýJ Clin Oncol. 2006;24(24):3953-3958. doi:
56.
Bang ÌýY-J, Kim ÌýY-W, Yang ÌýH-K, Ìýet al; CLASSIC trial investigators. ÌýAdjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù. 2012;379(9813):315-321. doi:
57.
Noh ÌýSH, Park ÌýSR, Yang ÌýH-K, Ìýet al; CLASSIC trial investigators. ÌýAdjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Oncol. 2014;15(12):1389-1396. doi:
58.
Sasako ÌýM, Sakuramoto ÌýS, Katai ÌýH, Ìýet al. ÌýFive-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 vs surgery alone in stage II or III gastric cancer.Ìý ÌýJ Clin Oncol. 2011;29(33):4387-4393. doi:
59.
Macdonald ÌýJS, Smalley ÌýSR, Benedetti ÌýJ, Ìýet al. ÌýChemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.Ìý ÌýN Engl J Med. 2001;345(10):725-730. doi:
60.
Park ÌýSH, Sohn ÌýTS, Lee ÌýJ, Ìýet al. ÌýPhase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin vs concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses.Ìý ÌýJ Clin Oncol. 2015;33(28):3130-3136. doi:
61.
Park ÌýSH, Lim ÌýDH, Sohn ÌýTS, Ìýet al; ARTIST 2 investigators. ÌýA randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.Ìý ÌýAnn Oncol. 2021;32(3):368-374. doi:
62.
Yang ÌýTS, Wang ÌýXF, Fairweather ÌýM, Sun ÌýYH, Mamon ÌýHJ, Wang ÌýJP. ÌýThe survival benefit from the addition of radiation to chemotherapy in gastric cancer patients following surgical resection.Ìý ÌýClin Oncol (R Coll Radiol). 2020;32(2):110-120. doi:
63.
Stiekema ÌýJ, Trip ÌýAK, Jansen ÌýEP, Ìýet al. ÌýThe prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.Ìý ÌýAnn Surg Oncol. 2014;21(4):1107-1114. doi:
64.
Al-Batran ÌýSE, Homann ÌýN, Pauligk ÌýC, Ìýet al. ÌýEffect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial.Ìý Ìý´³´¡²Ñ´¡ Oncol. 2017;3(9):1237-1244. doi:
65.
Terashima ÌýM, Yoshida ÌýK, Rha ÌýSY, Ìýet al. ÌýInternational retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).Ìý ÌýAnn Gastroenterol Surg. Published online October 20, 2021. doi:
66.
Riihimäki ÌýM, Hemminki ÌýA, Sundquist ÌýK, Sundquist ÌýJ, Hemminki ÌýK. ÌýMetastatic spread in patients with gastric cancer.Ìý Ìý°¿²Ô³¦´Ç³Ù²¹°ù²µ±ð³Ù. 2016;7(32):52307-52316. doi:
67.
Bonnot ÌýPE, Piessen ÌýG, Kepenekian ÌýV, Ìýet al; FREGAT and BIG-RENAPE Networks. ÌýCytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): a propensity score analysis.Ìý ÌýJ Clin Oncol. 2019;37(23):2028-2040. doi:
68.
Yang ÌýX-J, Huang ÌýC-Q, Suo ÌýT, Ìýet al. ÌýCytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.Ìý ÌýAnn Surg Oncol. 2011;18(6):1575-1581. doi:
69.
Mezhir ÌýJJ, Shah ÌýMA, Jacks ÌýLM, Brennan ÌýMF, Coit ÌýDG, Strong ÌýVE. ÌýPositive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients.Ìý ÌýAnn Surg Oncol. 2010;17(12):3173-3180. doi:
70.
Badgwell ÌýB, Cormier ÌýJN, Krishnan ÌýS, Ìýet al. ÌýDoes neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?Ìý ÌýAnn Surg Oncol. 2008;15(10):2684-2691. doi:
71.
Okabe ÌýH, Ueda ÌýS, Obama ÌýK, Hosogi ÌýH, Sakai ÌýY. ÌýInduction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.Ìý ÌýAnn Surg Oncol. 2009;16(12):3227-3236. doi:
72.
Badgwell ÌýB, Blum ÌýM, Das ÌýP, Ìýet al. ÌýPhase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma.Ìý ÌýAnn Surg Oncol. 2017;24(11):3338-3344. doi:
73.
Marutsuka ÌýT, Shimada ÌýS, Shiomori ÌýK, Ìýet al. ÌýMechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis.Ìý ÌýClin Cancer Res. 2003;9(2):678-685.
74.
Takebayashi ÌýK, Murata ÌýS, Yamamoto ÌýH, Ìýet al. ÌýSurgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer.Ìý ÌýAnn Surg Oncol. 2014;21(6):1991-1997. doi:
75.
Fujitani ÌýK, Yang ÌýH-K, Mizusawa ÌýJ, Ìýet al; REGATTA study investigators. ÌýGastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.Ìý Ìý³¢²¹²Ô³¦±ð³Ù Oncol. 2016;17(3):309-318. doi:
76.
Lee ÌýYH, Lee ÌýJW, Jang ÌýHS. ÌýPalliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer.Ìý ÌýBMC Cancer. 2017;17(1):541. doi:
77.
Tey ÌýJ, Back ÌýMF, Shakespeare ÌýTP, Ìýet al. ÌýThe role of palliative radiation therapy in symptomatic locally advanced gastric cancer.Ìý ÌýInt J Radiat Oncol Biol Phys. 2007;67(2):385-388. doi:
78.
Jeurnink ÌýSM, van Eijck ÌýCH, Steyerberg ÌýEW, Kuipers ÌýEJ, Siersema ÌýPD. ÌýStent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review.Ìý ÌýBMC Gastroenterol. 2007;7:18. doi:
79.
Chen ÌýXJ, Chen ÌýGM, Wei ÌýYC, Ìýet al. ÌýPalliative gastrectomy vs gastrojejunostomy for advanced gastric cancer with outlet obstruction: a propensity score matching analysis.Ìý ÌýBMC Cancer. 2021;21(1):188. doi:
Views 9,097
Review
March 23, 2022

Surgical Management of Gastric Cancer: A Review

Author Affiliations
  • 1Department of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
JAMA Surg. 2022;157(5):446-454. doi:10.1001/jamasurg.2022.0182
Abstract

ImportanceÌý Surgery plays a critical role in the management of all stages of gastric cancer.

ObservationsÌý For patients with early gastric cancer and low risk of lymph node metastasis, endoscopic therapy or surgery alone is potentially curative. Novel techniques, such as sentinel lymph node biopsy, may allow for greater use of stomach-sparing procedures that could improve quality of life without compromising oncologic outcomes; however, experience with these techniques is rare outside of East Asia, and studies of long-term outcomes are still ongoing. Patients with later-stage localized gastric cancer benefit from more extensive lymphadenectomy and multimodality therapy, as they are at risk for nodal and distant metastases. There have been recent advances in chemotherapy that have led to improved survival, but the optimal sequencing of multimodality therapy is still being investigated. Better systemic therapy may also increase the role of surgery for patients with oligometastatic disease. There are ongoing studies examining the efficacy of peritoneal-directed therapies in both patients with low-volume peritoneal disease and patients at high risk of peritoneal recurrence.

Conclusions and RelevanceÌý The management of gastric cancer continues to evolve. Surgeons should be aware of novel surgical approaches currently under investigation as well as how surgery fits into the contemporary multidisciplinary approach to this disease.

×